Bristol-Myers' Yervoy fails in trial of prostate cancer patients
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb said its drug Yervoy failed to extend lives in a trial of prostate cancer patients but the therapy showed some benefit.